Page1 Tagravit R1- The Miracle of Encapsulated Retinol Retinol is among skincare s most popular and effective anti-aging ingredients, however, naked Retinol is highly sensitive to oxidation and degradation. Tagra's encapsulated Retinol, Tagravit R1, significantly enhances Retinol s stability, safety and efficacy- clinically confirmed. Please visit us at Booth 1032 (Amerilure), 2016 NYSCC Suppliers Day. Tagravit R1 Retinol is among skin care s most popular ingredients. Retinol is recognized as one of the most effective vitamins for anti-aging treatment due to its capacity to stimulate collagen production, accelerate cell reproduction and normalize skin keratinization. It also provides effective antioxidant support and Tagravit R1 regeneration. Its regular application significantly improves skin elasticity, smoothness, softness, resulting in younger, clearer and healthier looking skin. However, naked Retinol is highly sensitive to oxidation, degradation in the presence of air, sunlight, acidic conditions and heavy metals which eventually results in formulation discoloration. Tagra Biotechnologies has developed the most efficient delivery system which increases Retinol s stability significantly and therefore, the final products efficiency.
Page2 Tagravit R1 microcapsules are 30-40μm diameter loaded with 7% pure Retinol. Tagravit R1 is a non-nano product that is based on Tagra s Release on Demand (RND ) technology, which enables optimal isolation of the Retinol, therefore, protects it from instabilities and overcomes incompatibilities (Fig. 1). A B Fig.1: SEM micrograph of Tagravit R1 microcapsules. Magnification: (A.) 5K / bar- 3µm and (B.) 0.5K / bar - 10 µm. Encapsulated Retinol is easily released upon mechanical pressure, such as a rubbing action. The single layer polymeric shell collapses and breaks down into invisible particles, but still retains the payload to continue and deliver over time. Until the moment of application, Retinol remains fresh and potent, due to its high and improved stability (Fig.2).
Page3 Fig.2: Stability of encapsulated Retinol- Tagravit R1 microcapsules compared to naked Retinol, incorporated in O/W base cream at 40 C. Data presented as a mean of Retinol percentage of initial concentration. Clinical Evaluation of Tagravit R1 Tagravit R1 microcapsules were clinically tested by FOITS (Fast Optical In-Vivo Topometry of human skin) in the periorbital region. Results confirm significant smoothing effect using Tagrvit R1. Therefore, using Tagrvit R1 dramatically increases the end products efficacy and supports marketing claims.
Page4 Fig. 3: Mean changes of the roughness parameters (Rz* and Ra**) in the eye area after four weeks of treatment with Tagravit R1 microcapsules (1.45%) compared to control groups; treated and untreated with base cream, negative value indicates smoothing effect. * Rz -averaged depth of roughness ** Ra- arithmetic mean roughness Tagravit R1 microcapsules were RIPT tested (6 weeks study, n=50). No adverse reactions of any kind were noted therefore Tagravit R1 is consider as a nonprimary irritant and non-primary sensitizer to the skin.
Page5 Formulating with Tagravit R1: Easy to handle Compatible with all types*. of vehicle- gels, lotions, creams, emulsions Recommended usage level: up to 5% Tagravit R1 microcapsules should be added at the last stage of the formulation preparation using a low sheer paddle mixer, which makes incorporation very easy. No Nitrogen Environment is needed * Formulations should not contain more than 20% of Alcohols and/or Glycols in total. Tagra Biotechnologies is a leading manufacturer and supplier of microencapsulated ingredients for the cosmetic industry for more than 17 years. Tagra provides a wide range of innovative and highly functional active microencapsulated ingredients with stability, efficacy, and compatibilities. For more information and samples please contact: adi@tagra.com